NCT06543992View on ClinicalTrials.gov

Efficacy and Safety of Intrathecal Administration of Thiotepa in Combination With Methotrexate in Breast Cancer With Leptomeningeal Metastasis

PHASE2RecruitingINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

July 13, 2024

Primary Completion Date

December 13, 2026

Study Completion Date

December 13, 2026

Conditions
Leptomeningeal Metastasis of Breast Cancer
Interventions
DRUG

Intrathecal Administration of Thiotepa in Combination with Methotrexate via the Ommaya Reservoir

Patients received intrathecal 15mg MTX combination with 10mg thiotepa twice a week for 2 weeks (4 injections) followed by monthly injections of 15mg MTX combination with 10mg thiotepa until an event that meets the criteria for termination occurs.

Trial Locations (1)

210000

RECRUITING

Jiangsu Provincial People's Hospital, Nanjing

All Listed Sponsors
collaborator

The Affiliated Brain Hospital of Nanjing Medical University

OTHER_GOV

lead

The First Affiliated Hospital with Nanjing Medical University

OTHER